Leronlimab-PRO-140-DataSheet-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemELeronlimabCat.No.:HY-P99697CASNo.:674782-26-4Synonyms:PRO140作⽤靶点:CCR;HIV作⽤通路:GPCR/GProtein;Immunology/Inflammation;Anti-infection储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Leronlimab(PRO140)⼀种⼈化IgG4抗CCR5单克隆抗体。leronlimumab抑制CCR介导的HIV-1病毒和⼩⿏肿瘤模型肺转移。Leronlimab可⽤于HIV⾮精性脂性肝炎(NASH)和癌症的研究。体外研究Leronlimab(1-140mg/mL)bindstoCCR5-positivecellsupto98%[1].Leronlimab(80-1750μg/mL)blocksCCL5,CCL3,andCCL4-inducedcalciumresponsesinMDA-MB-231-CCR5cells[1].Leronlimab(175and350mg/mL)blocksMDA-MB-231cellinvasion[1].Leronlimab(10μg/mL;72hours)enhancesthecytotoxicityofdoxorubicinforMDA-MB-231cells[1].CellCytotoxicityAssay[1]CellLine:MDA-MB-231celllineConcentration:10μg/mLIncubationTime:72hoursResult:Increasedthecellskillingeffectinducedbydoxorubicin.体内研究Leronlimab(2mg;i.p.,twiceaweek)reduceslungmetastasisinmurinexenograftmodels[1].AnimalModel:FemaleNCIAthymicnu/nunudemicewithMB-MDA-231cellsexpressingLuc2-eGFPinjection[1]Dosage:2mg1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEAdministration:Intraperitonealinjection;2mg,twiceaweekResult:Reducedthevolumeofpulmonarymetastasesat8weeks.REFERENCES[1].JiaoX,etal.Leronlimab,ahumanizedmonoclonalantibodytoCCR5,blocksbreastcancercellularmetastasisandenhancescelldeathinducedbyDNAdamagingchemotherapy.BreastCancerRes.2021Jan23;23(1):11.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;021-589